Compare Abeona Therapeutics Inc (ABEO) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Vanguard International High Dividend Yield ETF — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Vanguard International High Dividend Yield ETF trades at $99.46. Which is the better fit depends on your goals.
| ABEO | VYMI | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $7.23 | $101.60 |
52-Week Low | $4.17 | $79.76 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
VYMI, Vanguard's International High Dividend Yield ETF, trades at $100.285, up 1.02% today, with a bullish technical outlook from moving averages. The fund offers a diversified portfolio of international dividend stocks with a low 0.07% expense ratio and an estimated yield near 4%, attracting over $2 billion in inflows in 2026 according to The Motley Fool (2026-05-30). Recent news highlights its role in inflation protection and diversification away from U.S. tech concentration.
The outlook for VYMI is positive, driven by strong dividend growth, attractive valuations compared to U.S. markets, and investor demand for international income. Risks include currency fluctuations, economic stagnation in key regions, and competition from other dividend ETFs. Analyst sentiment is generally favorable, emphasizing its defensive qualities in uncertain macroeconomic environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
